Experiment / E3NY24FKDWhole-Genome STARR-seq (WHG-STARR-seq)

Genome-wide HeLa-S3 ORI STARR-seq: inhibitor perturbation comparison

Resolving systematic errors in widely used enhancer activity assays in human cells

Episomal whole-genome STARR-seq tested 1,000–1,500 bp human genomic fragments in HeLa-S3 cells using the plasmid origin of replication (ORI) as the core promoter. Duplicate inhibitor-treated and untreated genome-wide screens were compared; the table contains the authors' union of final peak calls with condition-specific activity and differential statistics.

Processed tables are specific to each experiment. Column names, units, measurements, and table structure are not standardized across the database. Check this experiment’s column definitions and quality-control notes before comparing or combining data.

Perturbation & assay details

1 µM BX-795 (TBK1/IKKε inhibitor) + 1 µM C16 (PKR inhibitor), compared with no-drug control

Unbiased genomic DNA fragments were cloned into an episomal STARR-seq reporter with the ORI used as the core promoter. Reporter RNA was collected 6 h after electroporation and sequenced on an Illumina HiSeq 2500 as paired-end 50-cycle reads; inhibitor-treated and untreated screens were analyzed as a genome-wide comparison.

Processed data

50 rows per page. Click a cell to inspect its full value.

Visible columns (27 of 27)
Row
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Filters apply to this table only. The CSV download contains the complete processed table; filtered rows are available through the API.

Column dictionary · 27 definitions
element_id
Stable region identifier formatted as chrom:start-end using the source interval coordinates.
chrom
Chromosome of the tested genomic fragment.
start
Start coordinate of the source genomic interval.
end
End coordinate of the source genomic interval.
length_bp
Interval length in base pairs (end minus start).
inhibitor_peak_rank
Identifier/rank of the final peak in the inhibitor-treated screen (peak_N); blank when absent.
inhibitor_corrected_enrichment
Corrected STARR-seq enrichment over input for the inhibitor-treated screen.
inhibitor_pval
Peak-calling P value for the inhibitor-treated screen.
inhibitor_chromHMM
ChromHMM state at the inhibitor-treated peak summit.
inhibitor_genomic_annotation
Genomic feature annotation at the inhibitor-treated peak summit.
inhibitor_HeLaS3_DHS_sig
Study flag indicating significant HeLa-S3 DHS support for the inhibitor-treated peak (1/0).
inhibitor_Other_DHS_sig
Study flag indicating significant DHS support in other cell lines for the inhibitor-treated peak (1/0).
inhibitor_enriched_TE
Study flag for an enriched transposable-element family in the inhibitor-treated peak (1/0).
no_inhibitor_peak_rank
Identifier/rank of the final peak in the untreated screen (peak_N); blank when absent.
no_inhibitor_corrected_enrichment
Corrected STARR-seq enrichment over input for the untreated screen.
no_inhibitor_pval
Peak-calling P value for the untreated screen.
no_inhibitor_chromHMM
ChromHMM state at the untreated peak summit.
no_inhibitor_genomic_annotation
Genomic feature annotation at the untreated peak summit.
log2fc_inhibitor_vs_no_inhibitor
Differential activity log2 fold change calculated as inhibitor-treated over untreated.
p_over_adj
FDR-adjusted P value for enrichment/higher activity with inhibitor treatment.
p_under_adj
FDR-adjusted P value for depletion/lower activity with inhibitor treatment.
differential_fdr05
TRUE when either adjusted differential P value is < 0.05; otherwise FALSE.
differential_direction
Direction implied by the differential log2 fold change.
nearest_tss_ensembl75
Nearest transcript TSS Ensembl identifier from the source Ensembl 75 annotation.
nearest_tss_gene
Common gene name associated with the nearest transcript TSS.
is_inhibitor_peak
TRUE when the region is present in the final inhibitor-treated peak set.
is_no_inhibitor_peak
TRUE when the region is present in the final untreated peak set.

Quality control

Study QC was retained from the authors' pipeline: uniquely mapped reads with up to 3 mismatches and a maximum paired-end insert size of 2 kb; combined biological replicates; initial shortlisted regions required P < 1e-5 and enrichment >= 3; final peaks required corrected enrichment >= 4 (z = 3); peaks dominated by a single fragment (>50% of overlapping fragments) or overlapping ENCODE blacklisted regions were removed. The processed table additionally required a chr1–chr22/X coordinate, a 1,000–2,000 bp interval, finite differential statistics, and at least one condition-specific peak rank. All 12,424 source union-peak rows passed these packaging checks; 0 rows were excluded.

Curation notes

This is a region-focused enhancer screen, not an allele/variant MPRA. The table is the authors' merged final-peak comparison and therefore contains blank condition-specific fields for regions called only in the other condition. Some overlapping union rows share a source condition-specific peak rank; these rows were retained as distinct source intervals rather than silently collapsed. corrected_enrichment is an enrichment-over-input measure, whereas log2fc_inhibitor_vs_no_inhibitor is the paired differential activity statistic. Source files call the assembly hg19 (equivalent GRCh37-era coordinates). Focused BAC screens, luciferase validation, and STAP-seq samples were not included because the compact genome-wide peak comparison is the most directly useful activity table for this package.

Cite OpenMPRA

Cite the OpenMPRA database. Include your access date because the collection changes over time.

Please also cite the source studies when using their data.